Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats

Neuroscience Letters

Volumn 244, Issue 1, 1998, Pages 37-40

  Valverde, Olga ^a   Roques, Bernard P ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

BC 264; CCK(B) antagonist; Cholecystokinin; Conditioned place aversion; Devazepide; L 365,260; Morphine dependence; PD 134,308

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; BC 264; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEVAZEPIDE; MORPHINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AVERSION; DRUG EFFECT; HORMONAL REGULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MORPHINE ADDICTION; NONHUMAN; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

ANIMALS; ANTI-ANXIETY AGENTS; AVOIDANCE LEARNING; BENZODIAZEPINONES; CHOLECYSTOKININ; CONDITIONING, CLASSICAL; DEVAZEPIDE; INDOLES; MALE; MEGLUMINE; MORPHINE DEPENDENCE; PEPTIDE FRAGMENTS; PHENYLUREA COMPOUNDS; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032489415     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00118-9     Document Type: Article

References (30)

1. Agmo A., Gómez M. Conditioned place preference produced by infusion of met-enkephalin into the medial preoptic area. Brain Res. 550:1991;343-346.
2. Acquas E., Di Chiara G. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J. Neurochem. 58:1992;1620-1625.
3. Chang R.S.L., Lotti V.J. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc. Natl. Acad. Sci. USA. 83:1986;4923-4926.
4. B antagonists in mice: antagonism by naltrindole. Br. J. Pharmacol. 111:1994;956-960.
5. B receptors involved in animal models of anxiety. Pharmacol. Biochem. Behav. 49:1994;133-141.
6. Diana M., Pistis M., Muntoni A., Gessa G. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats. J. Pharmacol. Exp. Ther. 272:1995;781-785.
7. Durieux C., Coppey M., Zajac J.M., Roques B.P. Occurrence of two cholecystokinin binding sites in guinea pig brain cortex. Biochem. Biophys. Res. Commun. 137:1986;1167-1173.
8. B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Ann. N. Y. Acad. Sci. 713:1994;355-357.
9. Faris P.L., Komisaruk B.R., Watkins L.R., Mayer D. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science. 219:1983;310-312.
10. Fuxe K., Andersson K., Locatelli V., Agnati L.F., Hökfelt T., Skirboll L., Mutt V. Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection. Eur. J. Pharmacol. 67:1980;329-331.
11. B receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. Eur. J. Pharmacol. 261:1994;257-263.
12. B receptor antagonists. Brain Res. 572:1992;208-215.
13. Hökfelt T., Rehfeld J.F., Skirboll L., Ivemark B., Goldstein M., Markey K. Evidence for coexistence of dopamine and CCK in mesolimbic neurones. Nature. 285:1980;476-478.
14. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D.C., Hunter J.C., Pinnock R.D., Woodruff G.N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA. 87:1990;6728-6732.
15. B receptor heterogeneity. J. Pharmacol. Exp. Ther. 255:1990;1278-1286.
16. B selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res. 628:1993;254-262.
17. Ladurelle N., Roques B.P., Daugé V. The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK-8 in the posterior nucleus accumbens. J. Neurosci. 15:1995;3118-3127.
18. Li X.-M., Hedlund P.B., Fuxe K. Cholecystokinin octapeptide in vitro and ex vivo strongly modulates striatal dopamine D2 receptors in rat forebrain sections. Eur. J. Neurosci. 7:1995;962-971.
19. B antagonist PD-134,308. Br. J. Pharmacol. 114:1995;1031-1039.
20. Marshall F.H., Barnes S., Hughes J., Woodruff G.N., Hunter J.C. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J. Neurochem. 56:1991;917-922.
21. Mucha R.F., Van der Kooy D., O'Shaughnessy M., Bucenieks P. Drug reinforcement studied by the use of place conditioning in rat. Brain Res. 243:1982;91-95.
22. Noble F., Derrien M., Roques B.P. Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br. J. Pharmacol. 109:1993;1064-1070.
23. B receptor antagonists by ex vivo binding. Eur. J. Pharmacol. 253:1994;237-244.
24. Shippenberg T.S., Emmett-Oglesby M.W., Ayesta F.J., Herz A. Tolerance and selective cross-tolerance to the motivational effects of opioids. Psychopharmacology. 96:1988;110-115.
25. B receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology. 120:1995;400-408.
26. Valverde O., Maldonado R., Fournié-Zaluski M.C., Roques B.P. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J. Pharmacol. Exp. Ther. 270:1994;77-88.
27. B antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats. Psychopharmacology. 123:1996;119-126.
28. Valverde O., Tzavara E., Hanoune J., Roques B.P., Maldonado R. Protein kinases in the rat nucleus accumbens are involved in the aversive component of opiate withdrawal. Eur. J. Neurosci. 8:1996;2671-2678.
29. B receptors in the regulation of locomotor activity in the mouse. Psychopharmacology. 105:1991;393-399.
30. Voigt M., Wang R.Y., Westfall T.C. Cholecystokinin octapeptides alter the release of endogenous dopamine from the rat nucleus accumbens in vitro. J. Pharmacol. Exp. Ther. 237:1986;147-153.